REGENXBIO Inc. (RGNX): Total Assets
$453.03M
As of 2025-12-31
$386.62M
As of 2026-06-30
-18.4%
3-year compound annual growth
-8.5%
5-year compound annual growth
+7.4%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $453.03M | -2.8% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $465.99M | -18.8% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $573.97M | -31.1% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $833.27M | -25.2% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $1.11B | +57.3% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $708.16M | +42.2% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $497.91M | -8.4% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $543.81M | +173.7% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $198.68M | +15.0% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $172.73M | -22.0% | 2018-03-06, Balance as of period end |
| 2015-12-31 | $221.38M | n/m | 2017-03-07, Balance as of period end |
| 2014-12-31 | $3.49M | n/a | 2016-03-03, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $453.03M | -2.8% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $1.12B | -18.7% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $245.96M | -13.0% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $1.48B | +34.2% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $448.66M | +2.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $20.23M | -81.5% |
| Agenus Inc (AGEN) | 2025-12-31 | $226.80M | +0.2% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $501.90M | +31.1% |
Compare RGNX, DNA, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗